166 related articles for article (PubMed ID: 30927273)
1. Overexpression of TRIM26 suppresses the proliferation, metastasis, and glycolysis in papillary thyroid carcinoma cells.
Wang K; Chai L; Qiu Z; Zhang Y; Gao H; Zhang X
J Cell Physiol; 2019 Aug; 234(10):19019-19027. PubMed ID: 30927273
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of TRIM26 inhibits the proliferation, migration and invasion of bladder cancer cells through the Akt/GSK3β/β-catenin pathway.
Xie X; Li H; Pan J; Han X
Chem Biol Interact; 2021 Mar; 337():109366. PubMed ID: 33549581
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of tripartite motif containing 26 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling.
Tao JL; Luo M; Sun H; Zhao HM; Sun QS; Huang ZM
Kaohsiung J Med Sci; 2020 Jun; 36(6):417-422. PubMed ID: 32052576
[TBL] [Abstract][Full Text] [Related]
4. TRIM26 inhibits clear cell renal cell carcinoma progression through destabilizing ETK and thus inactivation of AKT/mTOR signaling.
Zheng D; Ning J; Deng H; Ruan Y; Cheng F
J Transl Med; 2024 May; 22(1):481. PubMed ID: 38773612
[TBL] [Abstract][Full Text] [Related]
5. Circ_100395 impedes malignancy and glycolysis in papillary thyroid cancer: Involvement of PI3K/AKT/mTOR signaling pathway.
Chen L; Zhuo D; Yuan H
Immunol Lett; 2022 Jun; 246():10-17. PubMed ID: 35447227
[TBL] [Abstract][Full Text] [Related]
6. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
Ma Y; Qin H; Cui Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of long non-coding RNA LINC00982 suppresses cell proliferation and tumor growth of papillary thyroid carcinoma through PI3K-ATK signaling pathway.
Xu D; Yu J; Zhuang S; Zhang S; Hong Z; Yuan C
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31262968
[TBL] [Abstract][Full Text] [Related]
8. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
[TBL] [Abstract][Full Text] [Related]
9. CircNDST1 promotes papillary thyroid cancer progression via its interaction with CSNK2A1 to activate the PI3K-Akt pathway and epithelial-mesenchymal transition.
Shu C; Wang S; Hu J; Xu M; Deng H; Maimaiti Y; Huang T
J Endocrinol Invest; 2023 Mar; 46(3):545-557. PubMed ID: 36306106
[TBL] [Abstract][Full Text] [Related]
10. CDK5RAP3 acts as a putative tumor inhibitor in papillary thyroid carcinoma via modulation of Akt/GSK-3β/Wnt/β-catenin signaling.
Feng X; Jiang J; Sun L; Zhou Q
Toxicol Appl Pharmacol; 2022 Apr; 440():115940. PubMed ID: 35219640
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic pseudogene DUXAP10 knockdown suppresses proliferation and invasion and induces apoptosis of papillary thyroid carcinoma cells by inhibition of Akt/mTOR pathway.
Li J; Jiang L; Liu Z; Li Y; Xu Y; Liu H
Clin Exp Pharmacol Physiol; 2020 Aug; 47(8):1473-1483. PubMed ID: 32215944
[TBL] [Abstract][Full Text] [Related]
12. LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway.
Sun W; Qian K; Guo K; Chen L; Xiang J; Li D; Wu Y; Ji Q; Sun T; Wang Z
Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):382-389. PubMed ID: 32227107
[TBL] [Abstract][Full Text] [Related]
13. FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.
Ma J; Huang X; Li Z; Shen Y; Lai J; Su Q; Zhao J; Xu J
J Cell Physiol; 2019 Aug; 234(10):17739-17748. PubMed ID: 30793770
[TBL] [Abstract][Full Text] [Related]
14. miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1.
Han J; Zhang M; Nie C; Jia J; Wang F; Yu J; Bi W; Liu B; Sheng R; He G; Kong L; Zheng L; Pang R; Ding Z; Chen L; Guan Q; Pan S; Meng X; Xu J; Liu L; Zhang J
Cell Death Dis; 2019 Feb; 10(3):195. PubMed ID: 30814512
[TBL] [Abstract][Full Text] [Related]
15. High Expression of
Wang X; Bi Y; Liu X; Liu L; Hao M; Tian M; Shang J
Cancer Biother Radiopharm; 2022 May; 37(4):313-323. PubMed ID: 34388030
[No Abstract] [Full Text] [Related]
16. Lysophosphatidic Acid Receptor 5 (LPAR5) Plays a Significance Role in Papillary Thyroid Cancer via Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin (mTOR) Pathway.
Wu CY; Zheng C; Xia EJ; Quan RD; Hu J; Zhang XH; Hao RT
Med Sci Monit; 2020 Jan; 26():e919820. PubMed ID: 31902939
[TBL] [Abstract][Full Text] [Related]
17. miR-4443 targets TRIM14 to suppress metastasis and energy metabolism of papillary thyroid carcinoma (PTC) in vitro.
Zuo XM; Sun HW; Fang H; Wu Y; Shi Q; Yu YF
Cell Biol Int; 2021 Sep; 45(9):1917-1925. PubMed ID: 34051007
[TBL] [Abstract][Full Text] [Related]
18. LPAR5 promotes thyroid carcinoma cell proliferation and migration by activating class IA PI3K catalytic subunit p110β.
Zhao WJ; Zhu LL; Yang WQ; Xu SJ; Chen J; Ding XF; Liang Y; Chen G
Cancer Sci; 2021 Apr; 112(4):1624-1632. PubMed ID: 33540491
[TBL] [Abstract][Full Text] [Related]
19. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/β-catenin signaling pathway.
Zhou Z; Liu Y; Ma M; Chang L
Biomed Pharmacother; 2017 Dec; 96():98-103. PubMed ID: 28965013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
